Artivion price target raised to $46 from $40 at Stifel

Stifel raised the firm’s price target on Artivion (AORT) to $46 from $40 and keeps a Buy rating on the shares. After having checked in with five cardiac surgeons about their latest On-X utilization trends, the firm tells investors that the physicians offered “constructive comments” and said that the broader cardiac surgeon community could be reacting incrementally more positively to the data in a January 2025 JACC medical-journal paper.